1	HOUSE OF REPRESENTATIVES - FLOOR VERSION		
2	STATE OF OKLAHOMA		
3	1st Session of the 58th Legislature (2021)		
4	COMMITTEE SUBSTITUTE		
5	FOR HOUSE BILL NO. 2510 By: Kannady of the House		
6	and		
7	Thompson of the Senate		
8			
9			
10	COMMITTEE SUBSTITUTE		
11	An Act relating to opioid abatement; amending		
12	Sections 3 and 6, Chapter 130, O.S.L. 2020 (74 O.S. Supp. 2020, Sections 30.5 and 30.8), which relate to the Political Subdivisions Opioid Abatement Grants Act; modifying scope of certain defined terms;		
13			
14	revising criteria for allocating opioid grant awards to eligible participants; eliminating requirement for		
15	legal services agreements; requiring initial opioid grant awards to be listed on a distribution table;		
16	and providing an effective date.		
17			
18			
19	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:		
20	SECTION 1. AMENDATORY Section 3, Chapter 130, O.S.L.		
21	2020 (74 O.S. Supp. 2020, Section 30.5), is amended to read as		
22	follows:		
23	Section 30.5 As used in the Political Subdivisions Opioid		
24	Abatement Grants Act:		

1 1. "Approved purpose" and "approved purposes" mean evidence-2 based, forward-looking strategies, programming and services used to: 3 expand the availability of treatment for individuals a. 4 affected by opioid use disorders, co-occurring 5 substance use disorders and mental health issues, develop, promote and provide evidence-based opioid use 6 b. 7 prevention strategies, provide opioid use disorder and co-occurring substance 8 с. 9 use disorder avoidance and awareness education, 10 d. decrease the oversupply of licit and illicit opioids, 11 support recovery from addiction services performed by e. 12 qualified and appropriately licensed providers, 13 f. treat opioid use, abuse and disorders, including early 14 intervention screening, counseling and support, 15 support individuals in treatment and recovery from q. 16 opioid use, abuse and disorder, 17 h. provide programs or services to connect individuals 18 with opioid use, abuse or disorder, or who are at risk 19 of developing opioid use disorder, co-occurring 20 substance use disorder and mental health issues, with 21 treatment and counseling programs and services, 22 address the needs of individuals who are involved, or i. 23 who are at risk of becoming involved, in the criminal 24 justice system due to opioid use, abuse or disorder

through programs or services in municipal and county criminal judicial systems, including prearrest and postarrest diversion programs, pretrial services and drug or recovery courts,

- j. address the needs of pregnant or parenting women with
 opioid use, abuse or disorder and their families,
 including babies with neonatal abstinence syndrome,
- 8 k. <u>address the needs of parents and caregivers caring for</u>
 9 babies with neonatal abstinence syndrome,
- 10 <u>1.</u> support efforts to prevent overprescribing and ensure
 appropriate prescribing and dispensing of opioids,
 12 <u>1. m.</u> support efforts to discourage or prevent misuse of
 opioids, including the oversupply of licit and illicit
 opioids,
- 15 support efforts to prevent or reduce overdose deaths m. n. 16 or other opioid-related harms, including through 17 increased availability and distribution of naloxone 18 and other drugs that treat overdoses for use by first 19 responders, persons who have experienced an overdose 20 event, families, schools, community-based service 21 providers, social workers and other members of the 22 public,

23 <u>n. o.</u> reimburse or fund law enforcement and emergency 24 responder expenditures relating to the opioid

1

2

3

4

1 epidemic, including costs of responding to emergency 2 medical or police calls for service, equipment, 3 treatment or response alternatives, mental health 4 response training and training for law enforcement and 5 emergency responders as to appropriate practices and precautions when dealing with opioids or individuals 6 7 who are at risk of opioid overdose or death, 8 reimburse attorney fees and expenses directly related o. p. 9 to opioid litigation incurred as part of legal 10 services agreements entered into before May 21, 2020, 11 support efforts to provide leadership, planning and q. 12 coordination to abate the opioid epidemic through 13 activities, programs or strategies for prevention and 14 recovery models, including regional intergovernmental 15 efforts and not-for-profit agency support,

16 <u>p. r.</u> support education of youths regarding the dangers of 17 opioid use, abuse and addiction,

18 q. s. fund training relative to any approved purpose,

- 19 <u>r. t.</u> monitor, surveil and evaluate opioid use, abuse or 20 disorder, or
- 21 s. u. provide opioid abatement as identified by the Oklahoma
 22 Opioid Abatement Board as consistent with the purpose
 23 of this act the Political Subdivisions Opioid
 24 Abatement Grants Act.

Provided that such strategies, programming and services occurred on
 or after January 1, 2006 2015;

2. "Board" means the Oklahoma Opioid Abatement Board;
3. "Eligible participant" means any political subdivision or
first responder organization that obtained legal representation or
participated in litigation with pharmaceutical supply chain
participants prior to the effective date of this act negatively
impacted by the opioid crisis;

9 4. "First responder organization" means a nonprofit
10 organization formed and in good standing under 501(c)(9) of the
11 Internal Revenue Code, whose primary function is to benefit public
12 safety employees;

13 5. "Nonapproved purpose" and "nonapproved purposes" mean 14 strategies, programming and services not falling within the 15 definition of "approved purpose" or "approved purposes" as defined 16 in this act section;

17 6. "Opioid funds" means all monetary amounts obtained through a
18 settlement or judgment by the Attorney General on behalf of the
19 State of Oklahoma related to opioid litigation involving
20 pharmaceutical supply chain participants, including the Purdue
21 Political Subdivisions Fund but excluding all other funds received
22 pursuant to the Purdue Settlement Agreement;

- 23
- 24

7. "Opioid grant awards" means grants funded from the Oklahoma
 Opioid Abatement Revolving Fund, awarded pursuant to the provisions
 of this act the Political Subdivisions Opioid Abatement Grants Act;

8. "Pharmaceutical supply chain" means the process and channels
through which controlled substances are manufactured, marketed,
promoted, distributed or dispensed;

9. "Pharmaceutical supply chain participant" means any entity
that engages in or has engaged in the manufacture, marketing,
promotion, distribution or dispensing of an opioid analgesic;
10. "Political subdivision" and "political subdivisions" have
the same meaning as provided in subparagraphs a, b, c and d of
paragraph 11 of Section 152 of Title 51 of the Oklahoma Statutes;

13 11. "Purdue Political Subdivision Fund" means the Twelve 14 Million Five Hundred Thousand Dollars (\$12,500,000.00) plus any 15 interest accrued thereon received from the Revive Oklahoma Health 16 Foundation consisting of funds from the Purdue Settlement Agreement 17 designed for distribution to political subdivisions which have 18 executed a release of legal claims as required by the Purdue 19 Settlement Agreement; and

12. "Purdue Settlement Agreement" means the settlement
agreement entered into by the State of Oklahoma and Purdue Pharma
L.P., Purdue Pharma, Inc. and the Purdue Frederick Company on March
26, 2019, and approved by the Court on April 2, 2019.

24

1 SECTION 2. AMENDATORY Section 6, Chapter 130, O.S.L. 2 2020 (74 O.S. Supp. 2020, Section 30.8), is amended to read as 3 follows:

Section 30.8 A. 1. The <u>Oklahoma Opioid Abatement</u> Board shall
conduct an initial disbursement of opioid grant awards to
participating eligible participants. Such opioid grant awards shall
be allocated amongst the different participating eligible
participants based on the following criteria, giving equal weight to
each criteria:

10	a.	the number of people per capita suffering from opioid
11		use disorder in the participating political
12		subdivision, or in the absence of such information,
13		the opioid prescription rate in the political
14		subdivision compared to the national average opioid
15		prescription rate,
16	b.	the number of opioid overdose deaths in the
17		participating political subdivision, and
18	c.	the amount of opioids distributed within the
19		participating political subdivision adopted by the
20		Board.
21	2. Grant	awards shall be subject to legal services agreements
22	entered into	by participating eligible participants based on the
23	grant awards.	-
24		

3. Initial opioid grant awards as provided for in this
 subsection shall be listed in an opioid grant award allocation
 matrix distribution table reviewed and approved by the Board to
 ensure that such awards adhere to the criteria as provided in this
 subsection adopted by the Board.

B. Following the awarding of opioid grant awards pursuant to
subsection A of this section, any remaining unencumbered balance in
the Oklahoma Opioid Abatement Revolving Fund shall be available to
the Board to award as grants to eligible participants; provided such
awards shall only be utilized by eligible participants for approved
purposes.

C. In the event an eligible participant merges, dissolves or ceases to exist, any remaining allocations of an awarded opioid grant award in excess of Five Hundred Dollars (\$500.00) shall be reallocated equitably based on the composition of the successor eligible participant or the successor eligible participants. SECTION 3. This act shall become effective November 1, 2021.

19 COMMITTEE REPORT BY: COMMITTEE ON PUBLIC HEALTH, dated 02/24/2021 - DO PASS, As Amended and Coauthored.

21

22

23

24

20

HB2510 HFLR BOLD FACE denotes Committee Amendments.